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Lung cancer is associated with signiﬁcant morbidity and
mortality and is a substantial burden to healthcare systems.
Physiotherapists play an important role in the management of
people with lung cancer. Advances in research over the past
decade, particularly supporting the use of exercise training, have
rapidly progressed the role of physiotherapy in lung cancer. This
review summarises the burden associated with lung cancer, the
management of lung cancer with a particular focus on physiother-
apy interventions, and future directions for research and clinical
practice.
What is lung cancer?
Cancer is a generic term for a heterogeneous group of diseases
that occur when abnormal cells are not destroyed by normal
metabolic processes, but instead proliferate andmetastasise out of
control.1 Lung cancer is the leading type of cancer diagnosed in
males worldwide.2 In females, lung cancer is the fourth most
common cancer diagnosed behind breast cancer, colorectal cancer
and cancer of the cervix uteri.2 Multiple factors are understood to
play a role in the induction of lung carcinogenesis. Tobacco
smoking is the leading cause.3 Other risk factors include exposure
to environmental or occupational carcinogens, pulmonary inﬂam-
mation, airﬂow limitation, chronic obstructive pulmonary disease
(COPD) and genetic predisposition.1,3,4 Weaker evidence links
physical inactivity and poor nutrition to an increased risk of lung
cancer.5 Non-small cell lung cancer (NSCLC) is the most common
type of lung cancer and accounts for 85% of new lung cancer
diagnoses.6 Small cell lung cancer accounts for a small proportion
of lung cancer diagnoses and is remarkably different to NSCLC in
terms of aetiology, prognosis and treatment.6 This review mainly
focuses on NSCLC, which is where the majority of physiotherapy
research exists.
Lung cancer is a disease predominantly seen in the elderly
population;more than80%of people diagnosedwith lung cancer are
aged 60years or older.6[38_TD$DIFF] ue to the high incidence of smoking amonghttp://dx.doi.org/10.1016/j.jphys.2016.02.010
1836-9553/ 2016 Australian Physiotherapy Association. Published by Elsevier B
creativecommons.org/licenses/by-nc-nd/4.0/).peoplewith lung cancer, multi-morbidities are common.7 Themost
commonof these is COPD, occurring in 40 to 70% of peoplewith lung
cancer.3,4 Due to the aetiology of lung cancer, the older age of
patients, andpresenceofmulti-morbidities, peoplewith lungcancer
[40_TD$DIFF]constitute a complex patient population to manage.
Medical management of lung cancer
The medical treatment of lung cancer has improved over recent
decades; however, lung cancer remains the leading cause of cancer
death worldwide and the overall 5-year survival rate is 14%.2 [39_TD$DIFF]
Medical treatments include surgical resection, chemotherapy,
radiotherapy and targeted agents, each of which is associated with
several side effects (Box 1). The choice of treatment combination
depends on the histological type, tumour location, cancer stage and
the patient’s degree of frailty.8
Surgical resection
Surgical resection of the tumour provides the best potential
chance of cure; however, approximately 70% of people present
with advanced inoperable disease and 25% of people with operable
disease are unﬁt for surgery.8 For those people who are able to
undergo surgery, surgical options include pneumonectomy,
lobectomy or sub-lobar resection.9 Lobectomy is the preferred
surgical approach over limited pulmonary resection in early stage
NSCLC as it is associated with lower rates of loco-regional
recurrence and improved survival.9 However, limited pulmonary
resection is advantageous in terms of preserving a greater amount
of lung volume, limiting postoperative physiological impairment
and, consequently, reducing postoperative complications and
hospital length of stay.9 Video-assisted thoracoscopic surgery is
the preferred approached over a thoracotomy incision and is
associated with: less pain, better shoulder range of motion and
improved function early after surgery; fewer postoperative
complications; decreased risk of intensive care readmission;
shorter hospital length of stay; and less need for inpatient
rehabilitation.8,10,11 [41_TD$DIFF] Following lung resection, clinically important.V. This is an open access article under the CC BY-NC-ND license (http://
Box 1. Common side effects resulting from lung cancer
treatments.
Surgery Chemotherapy Radiotherapy Molecular
targeted
therapies
 pain
 [8_TD$DIFF]cough
 fatigue
 fatigue
[1_TD$DIFF] nausea
[2_TD$DIFF] infection
 [9_TD$DIFF]vomiting
 [10_TD$DIFF]anaemia
 [11_TD$DIFF]diarrhoea
 [12_TD$DIFF]constipation
 loss of
appetite
 [13_TD$DIFF]hair [14_TD$DIFF]loss
 [15_TD$DIFF]mouth [16_TD$DIFF]ulcers
 [17_TD$DIFF]weight [18_TD$DIFF]gain
[19_TD$DIFF]or [20_TD$DIFF]loss
 [21_TD$DIFF]fatigue
 [17_TD$DIFF]cough
 [22_TD$DIFF]oesophagitis
 [23_TD$DIFF]nausea
 [24_TD$DIFF]vomiting
 [25_TD$DIFF]skin
[26_TD$DIFF]erythema
 [27_TD$DIFF]diarrhoea
 loss of
appetite
 hair loss
 [23_TD$DIFF]rigors
 [28_TD$DIFF]flu-like
symptoms
 [29_TD$DIFF]fatigue
 [30_TD$DIFF]nausea
 [31_TD$DIFF]vomiting
 [32_TD$DIFF]loss [33_TD$DIFF]of
[34_TD$DIFF]appetite
 [35_TD$DIFF]diarrhoea
 [36_TD$DIFF]constipation
 [37_TD$DIFF]skin and hair
changes
Invited Topical Review 61immediate postoperative pulmonary complications (PPCs) can
include respiratory failure (prolonged mechanical ventilation,
re-intubation or acute respiratory distress syndrome), pneumonia
and atelectasis requiring bronchoscopy.12 Reported rates of PPCs
vary from3 to 15%; this is partly due to a lack of consensus on a PPC
deﬁnition.13,14 Postoperative pulmonary complications are associ-
ated with increased hospital length of stay, intensive care
readmissions and mortality.13
Chemotherapy
Chemotherapeutic agents inhibit cell division in both cancerous
and non-cancerous cells and therefore result in side effects due to
the damage caused to normal cells.15 These side effects include
bone marrow suppression and resultant immunosuppression,
which are worst 2 weeks following treatment,16 and impaired
respiratory function, particularly diffusing capacity.17
Radiotherapy
External beam radiotherapy works by producing radiation,
which is targeted at the tumour, and results in apoptosis of the
cancerous cells. Side effects of radiotherapy occur due to the
associated formation of free radicals, widespread inﬂammatory
response and release of cytokines.15 Respiratory function, particu-
larly diffusing capacity, is impaired following radiotherapy.18
Molecular-targeted agents
Tumours are driven by genomic mutations and, increasingly,
the different genomes in NSCLC are being recognised and targeted
in the treatment of the disease. Targeted agents differ from
chemotherapy agents because they inhibit ‘pathways outside of
the nucleus that are required for malignant proliferation chemo-
therapy agents to act’, whereas chemotherapy agents act in the
nucleus by inhibiting the division of any rapidly dividing cells.19
In summary, lung cancer is associated with adverse physiologi-
cal impairments that arise from multiple causative factors,
including: the disease, treatment, multi-morbidities and pre-
existing harmful lifestyle behaviours. Consequently, this leads to
signiﬁcant disease burden.
Burden of lung cancer
Lung cancer is associated with higher disease burden, more
physical hardship and greater symptom distress than other cancer
types.6,20,21 Important symptoms include dyspnoea, fatigue,cough, pain and insomnia. These often occur as symptom clusters
and result in high patient distress and interference with daily
activities.21,22 Distress due to symptoms at the time of diagnosis is
predictive of mortality.20 Avoidance of symptom triggers (namely
physical activity) promotes a vicious cycle of inactivity and
functional decline; a phenomenon that is becoming well described
in the lung cancer literature and a cycle that is important for
physiotherapists to address.23
Cancer cachexia is a multi-factorial syndrome deﬁned by an
ongoing loss of skeletal muscle mass that cannot be fully reversed
by conventional nutritional support and leads to progressive
functional impairment.24 Clinically, cancer cachexia presents as a
combination of anorexia, metabolic alterations, loss of fat mass,
loss of skeletal muscle protein, loss of weight, impaired muscle
strength and fatigue.24 Important implications include reduced
ability to tolerate surgery, poor response to chemotherapy or
radiotherapy, impaired resilience to treatment, worse health-
related quality of life and increased mortality.24 At diagnosis,
people with lung cancer have reduced peripheral muscle strength
compared to healthy aged-matched peers.23 Skeletal muscle
dysfunction is likely to signiﬁcantly contribute to exercise
intolerance, particularly given that 70% of preoperative peak
exercise tests are stopped due to leg discomfort rather than
dyspnoea, and functional capacity is not related to spirometric
measures of lung function in this population.25,26 Peripheral
muscle strength declines further during and after lung cancer
treatment.23 Given the importance of peripheral muscle strength
to overall physical function, this impairment is an important
feature of lung cancer for physiotherapists to manage.
Following diagnosis, functional decline is common and rapid,
and activity limitations and participation restrictions commonly
ensue.23,27,28 At diagnosis, functional capacity is reduced com-
pared to healthy aged-matched peers.23 Functional capacity
measured preoperatively is predictive of postoperative outcomes,
including: respiratory failure, hospital length of stay, health-
related quality of life and survival.29 Functional capacity is also
predictive of survival in advanced lung cancer. [43_TD$DIFF]With every 50 m
improvement in the 6-minute walk test, survival improves by 13%
and people who walk at least 400 m before chemotherapy have
greater survival time.30,31 [42_TD$DIFF] A number of studies have reported that
functional capacity progressively declines after diagnosis; howev-
er, it is possible that this decline may be limited to the inoperable
population. In the surgical literature, most studies report
functional capacity to temporarily decline after lung resection
and then return to baseline by 3 to 6 months postoperatively.32,33
Conversely, people undergoing a pneumonectomy experience
sustained reductions in functional capacity postoperatively.33
Deterioration in functional capacity is also observed during
chemotherapy. An Australian study, including people with
operable and inoperable lung cancer, found an overall large
clinically and statistically signiﬁcantmean decline of 78m in the 6-
minute walk test over 6 months from diagnosis, suggesting that in
many people, functional capacity does not recover back to pre-
treatment levels in the short term.23 Not surprisingly, functional
capacity is the most common endpoint targeted by lung cancer
exercise trials to date.29
Physical inactivity is common and prevalent in lung cancer.
Studies have demonstrated that before surgery or treatment,
physical activity levels are low and less than those of healthy aged-
matched peers; this is based on self-report and objective
measures.23,34,35 United States and Australian data show that
only 26% and 40% of people with lung cancer meet cancer-speciﬁc
recommended physical activity levels, respectively.23,34 Impor-
tantly, before treatment, higher physical activity levels are seen in
people with better functional capacity, muscle strength, physical
function, nutritional status and self-determination to exercise, and
less anxiety, depression, distress, fatigue and symptoms.23,35 There
are many reasons why people with lung cancer may be inactive at
diagnosis: they might have been inactive for a large proportion of
their life (this is a risk factor for developing cancer) or physical
Granger: Physiotherapy management of lung cancer62activity levels may have already declined as the cancer progressed
prior to detection; the latter is more likely in the inoperable (more
advanced cancer) group. The cancer cachexia process starts early
and many of the features can progress signiﬁcantly before
diagnosis.24 Following surgery and treatment, physical activity
levels decline further. Agostini and colleagues36 found very low
levels of physical activity immediately postoperatively during the
inpatient stay (3% of preoperative steps/day); and Novoa and
colleagues37 found 25% and 49% reductions in steps per day
compared to preoperative values 30 days after lobectomy and
pneumonectomy, respectively. During cancer treatment, only 26%
of people meet the recommended activity levels27 and higher
physical activity levels are seen in people with better physical
function and health-related quality of life, and with lower
symptoms and depression.23 Importantly, it is unknown if this
is a causal relationship. It is possible that people are able to bemore
active because they have fewer symptoms and better health-
related quality of life; conversely, being active can reduce
symptoms (or desensitise the person to the symptoms) and
enhance quality of life.38 Six months after diagnosis, physical
activity levels remain reduced, with only 31% of survivors meeting
the recommendations.23 Survivors of lung cancer have long-term
reductions in physical activity and health-related quality of life,
and even experience fatigue 5 years following surgery.39,40
In summary, the physical and psychological implications of
lung cancer are severe, disabling and long-standing. They have
signiﬁcant ramiﬁcations for the patient, the family/carers and the
healthcare system. Physiotherapy management is important to
address these issues in lung cancer.
Physiotherapy management of lung cancer
A summary of the physiotherapy interventions that are used in
the management of lung cancer, along with the level of evidence
that underpins their use, is provided in Figure 1. Physiotherapy
interventions vary depending on the stage in disease trajectory and
timing relative to treatment. Physiotherapy services for lung
cancer have historically been hospital-based and focused on PPCs
after surgery.41 Other physiotherapy interventions, such as
exercise training, are less frequently performed as routine clinical
practice, despite the rapid growth of evidence supporting these
interventions over the last decade.
The cornerstone of physiotherapy management in lung cancer
should be prescription and delivery of exercise intervention.
Physical activity and exercise are vital components targeting three
main aspects of the cancer continuum: prevention, mortality and
morbidity. The American Cancer Society recommends that adults
with cancer engage in at least 150 minutes of moderate-intensity
aerobic exercise and two sessions of resistance exercise per week,
which is the same as the guidelines for the general adult
population.42,43 These recommendations are supported by strong
evidence derived predominantly from other cancer populations.
Higher physical activity levels are protective against developing[(Figure_1)TD$FIG]
Exercise in advanced disease 
Prehabilitation
M
Breathlessness manageme
Early pallia
Shoulder and thoracic cage ROM 
Benefit from the intervention
Several high-quality RCTs
Single high-quality RCT 
or several low-quality 
RCTs
Uncontrolled trials or 
expert opinion
Exercise-based rehabilitati
after surgery or curative treat
Figure 1. Interventions for the management of lung cancer with associated levels of e
ROM = range of motion, RCT = randomised, controlled trial.colon, pancreatic, endometrial and prostate cancer.42 Excessive
sedentary time, independent of moderate and vigorous physical
activity, is associated with increased risk of developing cancer.44
Higher physical activity levels after cancer diagnosis are associated
with reduced cancer-speciﬁc and all-cause mortality in breast,
colon and prostate cancer.45,46 Additionally, there is emerging
evidence linking post-diagnosis sedentary time with reduced
cancer-speciﬁc mortality as well.44 It is important to note that the
evidence, to date, in the general cancer population is limited by
lack of prospective research designs, longitudinal repeated
measurement of physical activity and control for other important
prognostic factors. The mechanisms between these associations
are notwell understood. It is hypothesised that exercisemodulates
circulating metabolic and sex-steroid hormone concentrations,
immune surveillance, and reduces systemic inﬂammation/oxida-
tive damage.47 In lung cancer speciﬁcally, there are only a small
number of studies investigating the link between physical activity
and development of lung cancer, and they report conﬂicting
results. There is a strong rationale for more research to be
conducted in this area, given the high potential clinical signiﬁcance
of physiotherapy and exercise to target lung cancer prevention and
survival as outcomes.
There is growing evidence for exercise interventions to reduce
cancer morbidity in lung cancer. The role of exercise in this
situation is to prevent deterioration and to maximise or restore
physical status prior to, during and following treatment. A previous
Cochrane review and three systematic reviews have been
conducted in the area of lung cancer speciﬁcally.48–51 The majority
of research, to date, has been performed in the preoperative or
postoperative treatment stage of lung cancer, with a smaller
number of studies investigating the role of exercise during
treatment or in advanced disease. The evidence supporting
exercise at these different time points is summarised in subse-
quent sections.
Prehabilitation
Prehabilitation is exercise delivered prior to surgery or
treatment. There are two clinical rationales for this. Prehabilitation
can be used for: operable patients (assessed to be ﬁt for surgery) to
maximise their physical status prior to the insult of surgery and
reduce postoperative morbidity; or inoperable patients (deemed
unﬁt for surgery based on cardiovascular impairment) to improve
their physical status enough for them to become operable. The
evidence supporting prehabilitation is still in its infancy. Most of
the research to date has been conducted in patients already
deemed operable and, generally, studies are small and limited by
lack of randomisation and/or control groups. Prehabilitation is not
yet part of routine clinical practice worldwide. Until further
research suggests otherwise, in already operable patients, it is
currently not recommended to delay surgery in order to undertake
prehabilitation, but rather use the time waiting for surgery
opportunistically to deliver prehabilitation as able.obility training 
nt 
tive care
exercises
Prophylactic postoperative
respiratory physiotherapy
on 
ment 
No benefit from the intervention
vidence.
Box 2. Example clinical pathway for patients after
thoracotomy.59[7_TD$DIFF]
Day 1 postoperative
 Sit out of bed in ward chair
 Ambulate  20 m on ward
 portable supplemental oxygen if required to keep SpO2 
95%
 portable suction if large air leak present
 assistance from one person if required
 gait aid if patient is unable to ambulate despite assistance
from one person
 Teach supported cough with towel wrap
 Commence respiratory physiotherapy if indicated (high-risk
patient or presence of PPC)
Day 2 postoperative
 Ambulate  50 m on ward
 portable supplemental oxygen if required to keep SpO2 
95%
 portable suction if large air leak present
 assistance from one person if required
 gait aid if patient unable to ambulate despite assistance
from one person
 Encourage supported cough
 Commence or continue respiratory physiotherapy if
indicated (high risk or presence of PPC)
Day 3+ postoperative
 Review by physiotherapist only if patient requires ongoing
mobility assistance or respiratory physiotherapy
Once intercostal catheters are removed
 Teach upper limb and thoracic mobility range of motion
exercises
 Physiotherapy completes a discharge mobility assessment
and provides any discharge planning as required for safety
Invited Topical Review 63The three systematic reviews in this area include a small
number of studies and an even smaller number of randomised,
controlled trials. There are nine studies inclusive of ﬁve random-
ised trials delivering exercise preoperatively and two studies
inclusive of one randomised trial delivering exercise both
preoperatively and postoperatively.48,49,51 To date, meta-analyses
have not been conducted due to lack of robust trials and
heterogeneity of measures and interventions.48,49,51 One random-
ised trial was stopped early due to poor recruitment (n = 9);52
three other randomised trials reported that prehabilitation was
associated with reduced hospital length of stay,53,54 PPCs,53,54 and/
or days needing a chest tube postoperatively,52 aswell as improved
respiratory function immediately post intervention.53,54 One
randomised trial 52 found conﬂicting results (no effect for hospital
length of stay or PPCs between groups) and currently the evidence
is not deﬁnitive. The systematic reviews, inclusive of the evidence
from non-randomised trials (mostly single-group studies), dem-
onstrate that people who undergo prehabilitation experience
improved functional capacity immediately after interven-
tion.48,49,51 There is limited research regarding the impact of
prehabilitation for inoperable patients and only one article
included in the systematic reviews addressed this: Fang and
colleagues55 included both participants who were deemed
operable and inoperable. Notably, their results demonstrated that
59% (n = 10/17) of the inoperable group were re-classiﬁed as
operable after exercise training and postoperatively there was no
statistical difference in PPC rate between the (initially) operable
group (34%) and (initially) inoperable group (40%). Since the
systematic reviews, one further randomised trial has been
published,56 as well as seven more non-randomised trials (mostly
single-group studies), which conﬁrm the previous ﬁndings. The
interventions tested in studies to date were predominantly
individual, supervised, outpatient-based and delivered ﬁve times
a week for a median of 4 weeks (range: 1 to 10 weeks). All studies
included aerobic exercise training and over half also included
resistance training. Whilst the evidence suggests that prehabilita-
tion is safe, questions remain regarding the feasibility. Generally,
the time between lung cancer diagnosis and surgery is short (<
1 month). Whilst some studies have shown successful effects of
short-term exercise training, the challenge exists in both clinical
and research settings to recruit, assess and commence exercise as
soon as possible after diagnosis, to maximise the length of time
available for exercise training. This issue may challenge the
translation of evidence supporting prehabilitation into clinical
practice.
In summary: the evidence supporting prehabilitation in lung
cancer is emerging, particularly for people already deemed ﬁt for
surgery. The small number of randomised trials conducted to date
provide preliminary evidence that prehabilitation may be beneﬁ-
cial in improving postoperative outcomes such as reduced hospital
length of stay and PPCs. The evidence in this area is limited by lack
of randomised trials and further work is required before
prehabilitation should be translated into routine clinical practice
for people undergoing surgery for lung cancer.
Perioperative management
Physiotherapy management in the immediate postoperative
period aims to treat PPCs, prevent musculoskeletal sequelae, and
facilitate early and safe discharge home. Hospital length of stay
after lung resection is generally short (5 to 6 days), although length
of stay is longer for patients who develop a PPC.14 Physiotherapy
principles include early mobilisation commenced on the ﬁrst
postoperative day, sitting out of bed and supported coughing.
Shoulder/thoracic cage exercises are prescribed after removal of
the intercostal catheter and are associated with reduced pain and
improved function in the short term.14,57
There is a lack of evidence to support to use of prophylactic
targeted respiratory physiotherapy interventions for routine
patientsmanaged on a clinical pathway following lung resection.51Physiotherapy management of this cohort has changed over the
last decade due to improvements in pain management and the
increasing use of video-assisted thoracic surgery and clinical
pathways. Thoracic surgery clinical pathways incorporate physio-
therapy principles and early mobilisation in daily nursing care and
are associated with reduced hospital length of stay (Box 2).58 The
landmark randomised trial by Reeve and colleagues14 demon-
strated no difference in PPC rate or hospital length of stay for
participants treated with prophylactic targeted respiratory phys-
iotherapy (deep breathing and coughing, mobilisation, progressive
shoulder/thoracic mobility exercises) plus usual care, compared to
usual care alone (no physiotherapy). Usual care included a clinical
pathway with early mobilisation. The PPC rate was low at 3.9% and
hospital length of stay was short at a median of 6 days.14 Whilst
this study is from a single centre in New Zealand and practice may
differ in other countries, it is the most deﬁnitive study conducted
to date and the only randomised trial in this area with a ‘no
physiotherapy’ control group.51 A number of other studies have
demonstrated that there is no added beneﬁt of adjuncts to
physiotherapy (incentive spirometry, intermittent positive pres-
sure breathing, ﬂutter, positive pressure devices, or breathing and
coughing exercises) on PPCs or length of stay.51 Therefore, for
hospitals using clinical pathways, physiotherapy services should
be focused on assessment (with or without mobilisation) of
thoracotomy patients on the ﬁrst postoperative day and ongoing
respiratory physiotherapy for high-risk patients or those who fall
off the clinical pathway (ie, do not achieve set pathway goals or
develop a PPC) (Box 2). Currently, there is no gold standard risk-
prediction tool with which to identify high-risk patients or those
who will develop a PPC; however, the known independent risk
factors for PPC are being aged 75 years, having a bodymass index
 30 kg/m2, an Anesthesiologists score  3, a current smoking
history and COPD.13 Independent factors predictive of lower
postoperative physical activity are being aged 75 years, having a
[(Figure_2)TD$FIG]
Study
Arbane32 a
Brocki62 b
Edvardsen59 b
Stigt61 c
Pooled 
SMD (95% CI)
Random
Favours control        Favours exercise
–1–2 0 21
Figure 2. Effect of exercise after lung resection on health-related quality of life.
a Global function of the European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire core 30.
b Physical component of theMedical Outcomes Study Short Form 36 General Health
Survey.
c Total score of the St George’s Respiratory Questionnaire.
Granger: Physiotherapy management of lung cancer64predicted forced expiratory volume in one second (FEV1) < 70%
and lower self-reported preoperative physical activity;36 this
suggests that these patients may be the ones to not meet clinical
pathway goals. Physiotherapy interventions used to treat PPCs
related to low lung volumes or sputum production/retention
include additional mobilisation, thoracic expansion exercises,
sustained maximal inspirations, active cycle of breathing techni-
ques and continuous positive airway pressure.
Physiotherapists are involved in the assessment of patients’
safety related to mobility for hospital discharge. Most patients
following lung resection are able to be discharged directly home;
however, a small proportion of patients (2% in an Australian
study)59 do not regain a satisfactory degree of independence
required for their social situation and home environment. These
patients can be transferred to a sub-acute inpatient rehabilitation
facility for a period of intensive physiotherapy/rehabilitation
targeting function and mobility.
Exercise following treatment
Exercise following surgery or treatment aims to restore physical
status (addressing loss of functional capacity and muscle strength,
which may occur during treatment) and to maximise function,
physical activity, psychological status and health-related quality of
life in the long term. The Cochrane review of exercise training after
lung resection included three randomised trials involving 178 par-
ticipants; it found signiﬁcant improvements in functional capacity
in favour of the intervention group (MD50mon the 6-minutewalk
test, 95% CI 15 to 85).50 A large number of single-group studies
have conﬁrmed this ﬁnding and demonstrated reduced symptoms
immediately after the intervention.48–51 Since the Cochrane review
there has been another randomised trial published;60 this trial
investigated the beneﬁt of high-intensity aerobic and resistance
training in people 5 to 7 weeks following surgery and similarly
found improvements in functional capacity (peak oxygen uptake)
in favour of the intervention group.60 The Cochrane review of post-
lung resection exercise on the outcomes of health-related quality
of life and FEV1 was inconclusive.
50,61,62 The addition of the
subsequently published trial60 to the meta-analysis continues to
show no signiﬁcant between-group difference for health-related
quality of life (SMD 0.34, 95% CI –0.14 to 0.81) (Figure 2; see
Figure 3 on the eAddenda for the detailed forest plot). Exercise
following treatment with curative intent has also been researched
in two randomised trials63,64 and a number of single-group
studies.48,63 Exercise in this situation is also associated with
improvements in functional capacity but not health-related
quality of life.48 Improvements in muscle strength are observed
in people who undergo resistance training.48 Exercise is alsoTable 1
General contraindications and precautions to exercise training.
Exercise Patient cohort Deta
All All Avo
 ha
 ne
 pl
 fev
 ex
Upper or lower limb lymphoedema Wea
Aerobic Peripheral limitation such as severe cancer cachexia
or muscle atrophy
Com
aero
Resistance Known or high risk for bony metastases Pres
com
High risk for osteoporosis Pres
High risk for bone fracture Pres
Cardiorespiratory limitation such as chemotherapy-induced
left ventricular dysfunction or severe anaemia
Gen
Postoperative patients Care
prio
befo
Stretches Postoperative patients Avoassociated with reduced cancer symptoms, anxiety and depres-
sion.48,63
The interventions examined in studies to date are generally
derived from the COPD and pulmonary rehabilitation literature,
which has been extensively tested and implemented into clinical
practice.65 Hence, the majority of studies include both aerobic
(ground walking, treadmill and/or stationary cycle) and resistance
training components and, currently, this combined training
approach is recommended. The addition of other components
such as breathing exercises, dyspnoea management, balance
exercises and stretches are used occasionally; however, the
independent contribution of these training components to the
resultant outcomes is unknown.48–51 The randomised trial by Salhi
and colleagues investigated the impact of whole body vibration
training as an alternative to resistance training.64 Results
demonstrated signiﬁcant improvements in functional capacity
and quadriceps muscle strength in the resistance training group;
however, this was not seen in either the whole body vibration
training group or control group, suggesting that whole body
vibration training is not an alternative to resistance training.64
Generally, exercise programs are supervised, run for 8 to 12 weeks
(range 4 to 14 weeks) and occur in an outpatient setting, although
inpatient and home-based programs have also been used.48–51 [3_TD$DIFF] The
exercise program should be individually tailored to the patient and
there are a number of factors to considerwhen prescribing exercise
for this population (Table 1).66 Careful pre-exercise screening andils
id exercise if:
emoglobin level < 80 g/l
utrophil count  0.5 x 109/microlitre
atelet count < 50 x 109/microlitre
er > 38 8C
treme fatigue or severe nausea
r compression garment during exercise
mence with resistance training and then progress to incorporate
bic training once muscle bulk and strength is improved
cribe with caution (recommend medical clearance before
mencement particularly for unstable bone or spinal metastases/fractures)
cribe with caution
cribe with caution
erally contra-indicated (recommend medical clearance before commencement)
with wound healing – often requires 6 to 8 weeks postoperatively for healing
r to commencement of resistance exercises (recommend medical clearance
re commencement)
id upper-limb stretches until removal of intercostal catheter
Invited Topical Review 65assessment, and monitoring throughout the exercise program is
advised;66 this includes consideration of the patient’s co-morbid-
ities. Tai Chi has been tested as an alternative form of exercise
training;67,68 a randomised trial involving patients following lung
resection found a 16-week Tai Chi program to be associated with
improved blood immune function.67,68
In summary, growing evidence suggests that exercise following
surgery/treatment is associated with improvements in physical
and physiological outcomes. Exercise in this setting is not yet
routine clinical practice. In Australia and New Zealand, < 25% of
patients are referred to pulmonary rehabilitation after lung
resection.41 Further randomised trials to strengthen the meta-
analyses conducted to datewill assist in the translation of evidence
into routine clinical practice.
Exercise in advanced disease
Exercise for people with advanced lung cancer aims to prevent
deterioration in physical and psychological status and maximise
independence. This is an area that is currently being actively
investigated. Several randomised trials are in progress in Australia,
Denmark, Germany, Belgium and Spain, and they will signiﬁcantly
add to the body of literature in the near future.69–72 The
preliminary data from two randomised trials73,74 and ﬁve non-
randomised trials (mostly single-group studies)75–79 published to
date are promising. The randomised trial by Henke and colleagues
demonstrated signiﬁcant differences in favour of the intervention
group for functional capacity, physical function, muscle strength,
symptoms and health-related quality of life, despite 63% of the
participants completing the trial (n = 29/46).73 Results from some
of the other studies have conﬁrmed these ﬁndings and demon-
strated improvements in functional capacity and muscle strength
in study completers. The exception to this are the studies by Temel
and colleagues78 and Jastrze˛bski and colleagues,79 which found no
statistically signiﬁcant change in these outcomes; although given
the rapid functional decline that occurs in advanced lung cancer,
maintenance is a positive result. Consistently, studies report no
change in global health-related quality of life.75–77 All studies
included patients during treatment. One randomised trial investi-
gated the beneﬁt of exercise during targeted therapy and
demonstrated that exercisewas safe and associatedwith improved
functional capacity, dyspnoea and fatigue.74 The exercise programs
tested were combined aerobic and resistance exercise delivered in
either outpatient,74,75,78 inpatient,73,79 or both in-patient and out-
patient settings.76,77 Neuromuscular electrical stimulation may be
an option for patients with severe symptoms that limit exercise
performance, although a recent randomised trial demonstrated
poor feasibility and no beneﬁtwhen administered during palliative
chemotherapy.80 Unfortunately, study completion rates in the
studies published to date are poor and range from 44 to 77%.75–78
Research involving people with advanced lung cancer is particu-
larly challenging, given the progressive nature of disease and short
survival time following diagnosis. A proportion of non-completion
in these studies is due to deaths.
Adherence to exercise training is an important issue in
advanced lung cancer. Adherence rates vary greatly. Adherence
to the exercise training sessions is higher for supervised
hospital-based training (inpatient setting 95%,76 outpatient
setting 44 to 77%)75–78 than for unsupervised home training
(9%).77 However, these adherence rates are from a small number
of pilot studies and home-based training has not been tested in
isolation. Home-based training is a highly appealing option.
People with lung cancer are already required to attend the
hospital frequently for appointments, investigations and treat-
ment, and therefore the ability to deliver physiotherapy/exercise
treatment away from the hospital is important. Home-based
training also allows increased access for people living in rural
areas and those without the ability to commute to the hospital.
Telerehabilitation also poses a potential alternative model
of delivery, where patients exercise at home whilst beingmonitored and supervised by health professionals located
elsewhere.81,82 Whilst the efﬁcacy of telerehabilitation has
not been investigated in lung cancer,48 recently, Hoffman and
colleagues reported that seven patients with lung cancer
successfully used a movement-sensing gaming consolea at
home to complete walking and balance exercises.83 Further
research should investigate whether home-based exercise
training is effective in advanced lung cancer and methods to
promote adherence to unsupervised exercise.
Physiotherapy involvement in palliative care
Early palliative care is important in advanced lung cancer. A
landmark study published in 2010 examined early palliative care
consisting of: structured meetings with palliative care clinicians
discussing physical and psychosocial symptoms; goals; decisions
about treatment; and coordination of care. Compared with
aggressive end-of-life care, this early palliative care improved
survival, health-related quality of life and mood for people with
metastatic lung cancer.84 Physiotherapy management of this
population includes management of breathlessness with breath-
ing retraining, relaxation techniques and activity pacing. In an
uncontrolled study, this was associated with improved breath-
lessness, functional capacity, physical activity levels and health-
related quality of life, and less distress.85 Commonly, patients
are admitted to hospital with signiﬁcant functional decline
(to a point where the patient or carer cannot manage at home),
or to a hospital/hospice in the end-of-life period for palliation.
At this point in the disease trajectory, the focus of
physiotherapy is on maximising the patient’s physical indepen-
dence and should be driven by his/her own goals and
wishes. Physiotherapy interventions include assistance with
mobilisation, provision of gait aids, and function-directed
exercises such as sit-to-stand practice to optimise daily physical
functioning.
Future directions for research and practice
The landscape of cancer research and treatment has changed
signiﬁcantly over the past two centuries. Commencing as an
incurable disease with rising incidence and mortality rates,
research and healthcare now allow cancer to be a curable disease
formany, withmortality rates declining and a rise in the number of
people living as cancer survivors in our communities. Unfortu-
nately, the picture for lung cancer speciﬁcally is remarkably less
favourable, and despite slight advances in medical treatment,
survival rates remain dreadful. Research is urgently needed to
address the efﬁcacy of new treatments to improve the chance of
cure in lung cancer. In 2005, the ﬁrst paper was published showing
that exercise improved survival in people with breast cancer.86
Exercise has the potential to inﬂuence inﬂammation, tumour
morphology, tumour growth and cancer recurrence.87,88 The
question of whether exercise improves survival in lung cancer is
important and remains unanswered. The challenge over the next
few decades is to test and establish the potential role that exercise
may play in treating lung cancer with the ultimate aim of
improving survival.
There are a number of limitations and gaps in the current
literature. The exercise studies are generally small, lack randomi-
sation and control groups, and rarely include long-term follow-up.
The interventions tested vary in terms of timing, exercise type,
duration and delivery. There is an abundance of studies in progress
that seek to address these questions (55 open studies on
ClinicalTrials.gov). Exercise in lung cancer is a growing area of
practice and has the potential tominimise the debilitating physical
and psychological decline that often occurs with lung cancer. As
evidence emerges, an important target for physiotherapy over the
next decadewill be to rapidly translate ﬁndings of research studies
into clinical physiotherapy practice.
Granger: Physiotherapy management of lung cancer66Footnotes: aNintendo Wii Fit plus, Nintendo Co, Ltd, Kyoto,
Japan.
eAddenda: Figure 3 can be found online at doi:10.1016/j.jphys.
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